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Our comprehensive gene expression profiles of the kidneys
in an anti-glomerular basement membrane (GBM) nephritis
model using DNA arrays revealed that allograft inflammatory
factor-1 (AIF-1) was one of the highly expressed genes. Here,
we explored the pathological significance of AIF-1 expression
in the kidneys. The expression pattern of AIF-1 mRNA and
protein in the kidneys of normal and diseased rats, such
as anti-GBM nephritis and puromycin aminonucleoside
nephrosis, was investigated by in situ hybridization,
immunohistochemistry, and immunoelectron microscopy.
Furthermore, the expression of AIF-1 in human kidneys
and urinary sediments was examined. AIF-1 was expressed
at both mRNA and protein levels in podocytes of normal
and diseased rats, and in infiltrating cells in anti-GBM
nephritis kidneys. The expression of AIF-1 in podocytes was
constitutive; positive in podocytes of both normal and
diseased rats. In humans, AIF-1 was expressed in podocytes
and infiltrating inflammatory cells, similarly. Moreover,
it was detected in urinary podocytes from patients with
immunoglobulin A nephropathy. These data document for
the first time that AIF-1, a constitutively expressed protein in
rat and human podocytes, is a novel molecular component of
podocytes, and that the upregulation of AIF-1 in an anti-GBM
nephritis model may mainly be a consequence of its
expression in infiltrating cells.
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Anti-glomerular basement membrane (GBM) nephritis
characterized by marked crescent formation and severe renal
impairment is a rapidly progressive glomerulonephritis and
an important cause of end-stage renal disease. The nephritis
induced by injection of rabbit anti-GBM serum in Wistar–-
Kyoto rats is a model of this disease. To elucidate this disease
state and establish its therapeutic strategy, it is important to
clarify the factors taking part in the regulation of inflamma-
tion in an anti-GBM nephritis model. A number of critical
factors, such as complements, proinflammatory cytokines,
chemokines, intercellular adhesion molecule-1, CD8þ lympho-
cytes, macrophages/monocytes, and macrophage metalloelastase
for the development of anti-GBM nephritis have been
revealed to date.1–7 We previously compared comprehensive
gene expression profiles of kidneys in anti-GBM nephritis
rats with those of control rats using DNA arrays, which
coveredB8800 probes,7 and discovered that allograft inflam-
matory factor-1 (AIF-1) was one of the highly expressed
(threefold) genes in this nephritis model.
AIF-1 is a 143 amino acid, an evolutionarily conserved,
calcium-binding protein8 encoded within the human leuko-
cyte antigen class III genomic region in humans, and its
expression is implicated in the inflammatory process. AIF-1
was originally cloned from activated macrophages in human
and rat atherosclerotic allogenic heart grafts undergoing
chronic transplant rejection.9 Subsequently, there were
reports of macrophages expressing AIF-1 in various diseases,
such as macrophages in the human allograft kidney under-
going clinical rejection,10 in the pancreatic islets in pre-
diabetic rats,11 in the skeletal muscle postdevascularization,12
and in the brain of experimental autoimmune encephalo-
myelitis.13 AIF-1 was also detected in microglial cells,13
activated T lymphocytes,14 balloon angioplasty-injured
vascular smooth muscle cells,15 dendritic cells,11 Kupffer
cells,16 bovine embryos,17 and mouse uterus;18 however, the
expression of AIF-1 in glomerulonephritis kidneys has not
been reported to date.
Podocytes are highly specialized epithelial cells that line
the outer surface of the GBM. Recently, it has been revealed
that the development of glomerular sclerosis in several
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human and experimental diseases is associated with the loss
of podocyte number in the glomerular capillary tuft.19–22 On
the other hand, recent observations have revealed that
changes in the quantification of urinary podocytes and their
fragments correlate with glomerular disease activity, suggest-
ing that urinary shedding of podocytes may represent a
measure of podocyte loss from the glomerulus.23–26 There-
fore, it is important to establish a method for the stable
detection of urinary podocytes and to find useful markers of
podocyturia for the assessment of podocyte injury in patients
with glomerular diseases.
The aim of this study was to explore the pathological
significance of AIF-1 in glomerulonephritis. Surprisingly,
AIF-1 was expressed in podocytes as well as in infiltrating
inflammatory cells. We found that AIF-1 could be detected in
human podocytes of kidney biopsy specimens and even in
urinary sediments of glomerulonephritis patients. AIF-1 could
be used as a novel marker for podocytes and podocyturia.
RESULTS
AIF-1 expression is enhanced in the rat anti-GBM nephritis
kidney
We previously performed a comprehensive analysis of gene
expression in kidneys of an anti-GBM nephritis model using
DNA microarrays,7 and found that AIF-1 expression was
significantly elevated (threefold) on day 7 after the induction
of this disease. We firstly performed Northern blot analysis to
confirm the enhanced expression of AIF-1 mRNA in kidneys
of this nephritis. As shown in Figure 1a, AIF-1 mRNA in
the kidneys of anti-GBM nephritis rats was enhanced in
comparison with those of untreated rats.
Subsequently, we used an in situ hybridization (ISH)
technique with rat AIF-1 cRNA probe to investigate which
components of the kidney expressed AIF-1 mRNA. As shown
in Figure 1b–f, AIF-1 mRNA was expressed in glomerular
capillary wall cells and infiltrating cells of the anti-GBM nephri-
tis kidneys. No expression of AIF-1 mRNA was detected
in the crescent cells. Similarly, in the untreated rat kidneys,
AIF-1 mRNA was expressed in glomerular capillary wall cells.
No significant signals were detected in sections examined by
the control sense cRNA probe.
These data indicate that AIF-1 mRNA was constitutively
expressed in podocytes, and suggest that upregulation of its
mRNA might be a consequence of the influx of AIF-1
expressing inflammatory cells into the anti-GBM nephritis
kidney.
AIF-1 is localized in podocytes
To investigate the localization of AIF-1 protein in the kidneys,
we performed immunohistochemical studies using anti-AIF-
1 antibody (Ab) on the anti-GBM nephritis kidney sections.
On all of the sections, AIF-1 was detected in glomerular
capillary wall cells, presumably podocytes, and infiltrating
cells, but not in crescent cells (Figure 2). The distribution
pattern of AIF-1-positive cells was almost identical to that of
AIF-1 mRNA-expressing cells. Similarly, AIF-1 was detected
in the glomerular capillary wall cells on untreated kidney
sections.
To ensure that AIF-1 was localized in the podocytes, we
performed co-immunofluorescence staining with anti-AIF-1
Ab and anti-podocalyxin Ab (a podocyte-specific marker).
In kidney sections of untreated, anti-GBM nephritis and
puromycin aminonucleoside (PAN) nephrosis rats, the
immunoreactivity for AIF-1 was detected on the same cells
which were positive for podocalyxin as shown in Figure 3,
indicating that AIF-1 protein was localized in podocytes. No
significant signals were detected in any sections incubated
with isotype-matched control Abs (data not shown).
To speculate a particular function or characteristic feature
of AIF-1, it is important to know its pattern of localization
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Figure 1 | AIF-1 mRNA expression is enhanced in the rat anti-GBM nephritis kidney and is localized in glomerular capillary wall cells.
(a) Total RNA (30mg) prepared from the whole kidneys of three untreated rats (lane 1) and three anti-GBM nephritis rats (lane 2) was hybridized
with 32P-labeled rat AIF-1 cDNA probe. AIF-1 mRNA expression in anti-GBM nephritis rat kidneys was higher than those of untreated rats.
(b–f) AIF-1 mRNA is localized in glomerular capillary wall cells and infiltration cells of rat kidneys. RNA in the kidney sections of (b–d) anti-GBM
nephritis rats or (e and f) untreated rats was hybridized with Dig-labeled rat AIF-1 cRNA probe. (b, c, and e) AIF-1 mRNA in glomerular capillary
wall cells and infiltrating cells (arrows) was hybridized with anti-sense cRNA probe (blue). (d and f) The sense cRNA probe was used as a control.
The photos are representatives of slides prepared from two pairs of untreated and anti-GBM nephritis rats (original magnification: b–f,  400).
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within the cells. We therefore performed an immunoelectron
microscopic study using anti-AIF-1 Ab labeled with 10 nm
gold (Figure 4). In the kidneys of untreated rats, gold parti-
cles were diffusely distributed in the cytoplasm of podocytes
without specific localization. In the kidneys of anti-GBM
nephritis and PAN nephrosis rats, the pattern of localization
was similar to that of untreated rats; thus, the localization of
AIF-1 in podocytes was not different between normal and
injured podocytes.
AIF-1 is a novel marker for podocytes and podocyturia in
humans
As AIF-1 is evolutionarily conserved, we subsequently
performed an immunohistochemical study on human
specimens (Figure 5a–c). In the kidney specimen from grafts
for transplantation, AIF-1 was similarly detected in podo-
cytes. In the specimen of transplanted kidney graft with acute
rejection, AIF-1 was detected in infiltrating inflammatory
cells as well as podocytes.
Recently, the detection of podocytes in urine sediments
has been reported to indicate the occurrence of severe
podocyte injury in glomeruli.23–28 To our knowledge,
podocalyxin is the most reliable marker of podocytes and
their fragments in human urinary sediments. A number of
podocyte-specific markers have been tested for this
purpose, but none were as sensitive and inclusive as
podocalyxin.27 Consequently, we sought to assess whether
AIF-1 protein could be a useful marker of podocytes and
their fragments in urinary sediments. Immunofluorescence
microscopy was employed to examine urinary sediments of
five patients with immunoglobulin (Ig)A nephropathy
double stained with anti-AIF-1 Ab and anti-podocalyxin
Ab. Figure 5d–l demonstrates the identical reaction of
anti-podocalyxin and anti-AIF-1 antibodies to podocytes
and their fragments in the urinary sediments of the patients
with IgA nephropathy. No significant signals were detected
in all sections incubated with isotype-matched control
Abs (data not shown). These findings indicate that AIF-1 could
be a novel marker for podocytes and podocyturia in humans.
Although the reaction pattern of anti-podocalyxin and
anti-AIF-1 antibodies was almost same in all sediments, some
AIF-1-positive cells were negative for podocalyxin. Then,
because AIF-1 is expressed in inflammatory cells9,14 and
inflammatory T cells and macrophages appear in urine of
active glomerulonephritis,29 we performed double stained
immunofluorescence microscopy with anti-CD3 (a T-cell
marker) or anti-CD14 (a macrophage marker) instead of
anti-podocalyxin Ab in urinary sediments of three patients
with IgA nephropathy. We found that some cellular
components positive for AIF-1 were positive for CD3 or
CD14 (Figure 5f, i, and l), indicating that AIF-1-positive cells
might, in part, include T cells or macrophages.
DISCUSSION
In this study, we have shown that AIF-1 mRNA is expressed
in podocytes and infiltrating cells in rat kidneys, and AIF-1
protein is located in the cytoplasm of podocytes and
infiltrating cells in rat and human kidneys. Furthermore,
we found that AIF-1 protein could be a novel podocyte
marker in urinary sediment.
To our knowledge, the report by Grimm et al.10 is the
single available report about AIF-1 in the kidney, and by
which it was concluded that increased infiltration of AIF-1-
positive macrophages in renal allograft undergoing rejection
can distinguish clinical rejection from subclinical rejection.
We also found that infiltrating cells in the interstitium of an
anti-GBM nephritis kidney express AIF-1. As the expression
of AIF-1 in macrophages is induced by the release of
T helper (Th)1 cytokines such as interferon-g,9 and both
renal transplant rejection and anti-GBM nephritis are
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Figure 2 | AIF-1 protein is localized in glomerular capillary wall
cells and infiltrating cells of rat kidneys. Serial paraffin sections
from (a) untreated rat and (b and c) anti-GBM nephritis rat kidneys
were stained with anti-AIF-1 Ab. (a) The glomerular capillary wall cells
of untreated rats were stained with anti-AIF-1 Ab (brown). (b and c)
The glomerular capillary wall cells and infiltrating cells (arrows) of
anti-GBM nephritis rats were stained with anti-AIF-1 Ab (brown), but
AIF-1 protein was not detected in the crescent cells. Serial paraffin
sections from kidneys of (d) untreated rats and (e) anti-GBM nephritis
rats were stained with normal goat IgG as controls. The photos are
representatives of slides prepared from four pairs of untreated and
anti-GBM nephritis rats (original magnification: a–e,  400).
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associated with Th1 response,30,31 it is possible that a
common pathway may have caused cell infiltration in these
different pathologies. Additionally, we found for the first
time that AIF-1 is expressed in podocytes, which was not
documented by Grimm et al., probably because of the
difficulty of AIF-1 staining. In our study, antigen retrieval
treatment was necessary for the immunohistochemical
analysis of AIF-1 in the paraffin-embedded sections, and
the stainability of AIF-1 in human kidney specimens was
unstable in comparison with that in rat kidney specimens.
AIF-1 mRNA was detectable in the podocytes of both
untreated and anti-GBM nephritis kidneys by ISH; however,
AIF-1 mRNA expression was enhanced in the latter by
Northern blot analysis. This is probably because of its
additional expression in the infiltrating cells in the anti-GBM
nephritis kidney, although upregulation in the podocytes
cannot be excluded. Morohashi et al.32 investigated trini-
trobenzene sulfonic acid-induced colitis, a model for Th1-
type disease, in AIF-1 transgenic mice that express high levels
of AIF-1 in lymphoid tissues and the colon. They showed that
the trinitrobenzene sulfonic acid-induced colitis in AIF-1
transgenic mice was ameliorated compared with that in non-
transgenic littermates, suggesting that AIF-1 regulates Th1-
type inflammatory responses. The overexpression of AIF-1 in
a macrophage cell line results in the augmentation of
cytokine production of Th2 type.33 Thus, augmentation of
AIF-1 expression may reflect some feedback mechanisms
leading to the suppression of Th1 responses.
Podocytes are terminally differentiated cells that line the
outer surface of the GBM.34 Based on accumulating evidence
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Figure 3 | AIF-1 protein is localized in podocytes in rat kidneys. In the renal cortex of (a, d, and g) untreated, (b, e, and h) anti-GBM
nephritis, and (c, f, and i) PAN nephrosis rats, indirect double-labeled immunofluorescence staining with (a–c) anti-AIF-1 Ab (green) and (d–f)
anti-podocalyxin (podocyte marker) Ab (red) was performed. (g–i) The merged pictures (yellow) show that AIF-1 is localized in the same cells
that are positive for podocalyxin. The photos are representatives of slides prepared from three pairs of untreated and anti-GBM nephritis rats
and two PAN nephrosis rats (original magnification: a–i,  400).
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Figure 4 | AIF-1 protein is localized in the cytoplasm of podocytes
diffusely. In the renal cortex of (a and b) untreated, (c) anti-GBM
nephritis, and (d) PAN nephrosis rats, immunoelectron microscopy using
anti-AIF-1 Ab labeled with 10 nm gold was performed. In all sections,
gold particles were diffusely distributed in the cytoplasm of podocytes
without specific localization. Bar=1 mm. Asterisk shows GBM.
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that podocyte failure decisively accounts for the initiation of
progressive renal diseases as well as maintaining the
progression to end-stage renal failure,35 several investigators
have recently focused on proteins that compose the
podocytes. In this study, we found that AIF-1 is a novel
podocyte component protein. AIF-1 is associated with cell
migration and proliferation by Rac1 activation and granu-
locyte colony-stimulating factor expression in vascular
smooth muscle cells and macrophages.15,36,37 Additionally,
AIF-1 colocalizes with F-actin in unstimulated vascular
smooth muscle cells, but translocates to lamellipodia on
stimulation with platelet-derived growth factor.36 As both
podocytes and vascular smooth muscle cells share a common
feature, which is the mesenchymal cell origin,38 AIF-1 might
play a role in podocytes. In our immunoelectron microscopic
study, AIF-1 in the podocytes of untreated rats was diffusely
located in the cytoplasm, raising the possibility that AIF-1 in
podocytes may colocalize with actin. However, the transloca-
tion of AIF-1 in podocytes was not detected under the
inflammatory conditions of anti-GBM nephritis or under cell
damage as in PAN nephrosis. These data suggest that AIF-1
may not play such a role in podocytes, probably because they
are terminally differentiated cells and do not typically
proliferate like other cells.
The quantification of podocytes in the cytospin of urine
sediments has recently become an established method to
assess the degree of podocyte injury in patients with
glomerular diseases.23–26 Podocalyxin has been widely used
as a marker of podocytes and their fragments in human
urinary sediments. Although cytospin sediments have been
shown to be stained with other podocyte-specific markers,
such as GLEPP1, podocin, and synaptopodin, samples
positive for those markers were approximately 30–40% of
samples positive for podocalyxin.27 Hara et al.23 confirmed
that fragments of podocyte (podocalyxin-positive granular
structures) in human urinary sediments were negative for
antibodies that react with specific components of podocytes
such as nephrin, ZO-1, and a3 integrin. In this study, urinary
podocytes and podocalyxin-positive granular structures
exhibited the almost same degree of positivity to anti-AIF-1
and anti-podocalyxin antibodies, although some AIF-1-
positive cells were macrophages and T cells in urine
sediments. Therefore, AIF-1 could be one of the podocyte
markers in human urinary sediments. In conclusion, we have
found for the first time that AIF-1 is a novel cytoplasmic
component of podocytes and one of the few markers of
urinary podocytes; however, the characteristics and functions
of AIF-1 in podocytes remain unclear. Further study may
help to elucidate this issue.
MATERIALS AND METHODS
Animals and experimental models
Male Wistar–Kyoto rats (7 weeks old, weighing 190–210 g) were
purchased from Charles River Japan (Yokohama, Japan). Animal
care was performed in accordance with the guidelines of Niigata
University (Niigata, Japan). For the induction of rat anti-GBM
nephritis, rats were randomly divided into two groups. Each group
included six rats. On day 0, rats in one group were injected
intravenously with rabbit anti-rat GBM serum (200 ml, containing
about 2 mg of IgG), which was prepared as described previously.5
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Figure 5 | AIF-1 protein is localized in glomerular podocytes and infiltrating cells in the human kidney and exists in urinary podocytes
and their fragments. (a and b) In three normal human kidneys, podocytes were stained with anti-AIF-1 Ab (brown), as in the case of rats. (c) In
the human allograft kidney with acute rejection, infiltrating cells (arrows) were stained with anti-AIF-1 Ab (brown). (d–l) In the urinary sediments
of five IgA nephropathy patients, immunofluorescence microscopic study by indirect double stain with (d–f) anti-AIF-1 Ab (green) and
(g–h) anti-podocalyxin Ab (red) or (i) anti-CD14 Ab (red) was performed. (j–l) The merged pictures (yellow) show that AIF-1 protein exists in
podocytes and their fragments, which also have a podocalyxin component, and some cellular components positive for AIF-1 were positive for
CD14. The photos are representatives of slides prepared from five IgA nephropathy patients (original magnification: a–c,  400, d–l,  400).
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On day 7, the rats were anesthetized by diethyl ether inhalation and
killed after removal of the kidneys. Renal tissues were snap frozen
for Northern blot analysis, or fixed in 4% paraformaldehyde for ISH,
or in Carnoy’s fluid for immunohistochemical analysis. As a
negative control, rats in the other group did not receive the anti-
GBM serum, and the kidney samples were collected in the same way
as described above. PAN nephrosis was induced by a single
intravenous injection of PAN (Sigma, St Louis, MO, USA) at a
dose of 7 mg/100 g of body weight in phosphate-buffered saline
(PBS). Two rats were killed under diethyl ether anesthesia 10 days
after PAN injection, and kidneys were removed and processed for
immunohistochemical analysis.
Patients
Urine samples and kidney specimens were obtained from nine
patients from 2000 to 2006. The patients were three kidney
transplant donors (44, 49, and 53 years, female, proteinuric level,
0.01–0.04 g/day), a kidney transplant recipient with acute rejection
(Banff diagnostic category aA) (30 years, male), and five patients
with IgA nephropathy diagnosed by renal biopsy (40–51 years
(mean, 45.2 years), proteinuric level, 0.47–3.3 g/day (mean, 1.8 g/
day)). The donor kidneys were considered to be normal controls.
This study was approved by the ethics committee of Niigata
University Hospital. Informed consent was obtained from the
patients.
Template preparation
To amplify cDNA from the rat AIF-1 coding region (448 bp)
by PCR, two primers, 50-AGCCAGAGCAAGGATTTGCAG-30 as
a forward primer, and 50-CCTCCAATTAGGGCAACTCAG-30 as
a reverse primer, were used. The PCR product was inserted into a
pGEM-T (Promega Corporation, Madison, WI, USA) cloning
vector for Northern blot analysis and for ISH.
Northern blot analysis
After removal of the kidneys, renal tissue was snap frozen in liquid
nitrogen and stored at 801C until analysis. After homogenization
of samples from three untreated or three anti-GBM nephritis rats,
total RNA was extracted using RNA extraction solution (ISOGEN,
Nippon Gene, Tokyo, Japan), following the manufacturer’s protocol.
For Northern blotting, 30 mg of total RNA was loaded per lane,
electrophoresed on a 1.5% agarose gel containing formaldehyde, and
transferred to a nylon membrane (Hi-bond N) (Amersham
Biosciences Corp., Piscataway, NJ, USA). 32P-labeled cDNA probe
for rat AIF-1 was synthesized using Random Primed DNA Labeling
Kit (Roche Diagnostics, Mannheim, Germany) and hybridized with
the RNA. After washing, glyceraldehydes-3-phosphate dehydrogen-
ase expression was detected on the same membrane as an internal
control.
In situ hybridization
ISH with AIF-1 mRNA was conducted as described previously.39 We
tried ISH with two pairs of untreated and anti-GBM nephritis rat
kidneys. For digoxigenin-labeled probe synthesis, in vitro transcrip-
tion was performed using a Dig RNA labeling kit (SP6/T7; Roche).
AIF-1 anti-sense cRNA probe and sense probe (negative control)
were synthesized from the same template and used for hybridiza-
tion. The following immunological detection procedure was
performed using Dig nucleic acid detection kit (Roche).
Immunohistochemistry
Samples were embedded in paraffin by routine methods. Serial
sections of four pairs of untreated and anti-GBM nephritis kidney
tissues (4mm) were deparaffinized in xylene, rehydrated in a graded
alcohol series, and washed in PBS. All sections were pretreated with
hydrated autoclaving at 1211C for 15 min in 10 mM citrate solution
for antigen retrieval. Slides were blocked with 3% H2O2 in PBS
for 10 min, and 3% bovine serum albumin in PBS for 15 min. For
detection of AIF-1, the slides were incubated with goat anti-rat
or human AIF-1 polyclonal Ab (Abcam, Cambridge, UK) overnight
at 41C, and treated with peroxidase-conjugated rabbit anti-goat IgG
Ab (DAKO, Carpinteria, CA, USA) as the secondary Ab at a dilution
of 1/100. The immune complex was detected with 3,30-diamino-
benzidine tetrahydrochloride (DAKO), and counterstaining was
performed with hematoxylin. Control sections were incubated with
normal goat IgG (Zymed Laboratories, South San Francisco, CA,
USA) instead of anti-AIF-1 Ab.
Immunofluorescence microscopy
Frozen three pairs of untreated and anti-GBM nephritis rat and two
PAN nephrosis rat kidney tissues were cut into 3-mm sections.
Urinary sediments from 50 to 200 ml of freshly voided urine were
washed twice with ice-cold PBS and pelleted by centrifugation.
These urinary sediments were then prepared on glass slides
(cytospin preparations) and fixed in acetone for 5 min at 41C. The
sections and urinary sediments were incubated with anti-AIF-1 Ab
(5mg/ml) for 90 min at room temperature and treated with 1/40-
diluted rabbit anti-goat IgGs fluorescein isothiocyanate conjugate
(Zymed Laboratories) as the secondary Ab for 60 min at room
temperature. After extremely washing with PBS, the slides were
incubated with mouse anti-podocalyxin monoclonal Ab (4D5) as
a podocyte marker40,41 or rhycoerythrin-conjugated mouse anti-
human CD14 monoclonal Ab (BD Biosciences, San Jose, CA, USA)
or rhycoerythrin-conjugated mouse anti-human CD3 monoclonal
Ab (BD Biosciences). Tetramethyl rhodamine isothiocyanate con-
jugate rabbit anti-mouse immunoglobulin (DAKO) was used as a
secondary Ab for 4D5. The immunofluorescent signals were
detected by immunofluorescence microscopy. Control sections were
incubated with isotype-matched control Abs; goat IgG (Zymed
Laboratories) instead of anti-AIF-1 Ab and mouse IgG2a (BD
Biosciences) instead of 4D5.
Immunoelectron microscopy
For immunogold staining with anti-AIF-1, ultracryosections of
normal, anti-GBM nephritis and PAN nephrosis rat kidney were
mounted on collodion /carbon-coated nickel grids (150 mesh).
Aldehyde groups were quenched with 0.01 M glycine in PBS and
incubated overnight at 41C with anti-AIF-1 (5mg/ml). They were
then incubated with rabbit anti-goat IgG (Hþ L) coupled to 10-nm
gold (BBInternational, UK) diluted 1:20 in PBS for 2 h at room
temperature. After immunostaining, they were washed with PBS,
fixed with 2.5% glutaraldehyde, contrasted with 2% uranyl acetate
for 10 min, absorption stained with 3% polyvinyl alcohol containing
0.2% uranyl acetate for 10 min, and viewed with a JEOL 100-CX
electron microscope.
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